1. 2219 Intratumoral injection of the oncolytic immunotherapeutic Pexa-Vec (JX-594) in liver tumors and hepatocellular carcinoma: Recommendations for clinical practice. (September 2015) Authors: Lencioni, R.; Kim, C.W.; Rose, S.C.; Breitbach, C.J.; Burke, J.M.; Hickman, T.; Kirn, D.H.; Stojkowitz, N.; Lusky, M.; Homerin, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S405 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). (3rd August 2019) Authors: Moehler, M.; Heo, J.; Lee, H.C.; Tak, W.Y.; Chao, Y.; Paik, S.W.; Yim, H.J.; Byun, K.S.; Baron, A.; Ungerechts, G.; Jonker, D.; Ruo, L.; Cho, M.; Kaubisch, A.; Wege, H.; Merle, P.; Ebert, O.; Habersetzer, F.; Blanc, J.F.; Rosmorduc, Olivier Journal: Oncoimmunology Issue: Volume 8:Number 8(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗